お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
611766

急性骨髄性白血病 (AML) :動態市場の予測

Acute Myeloid Leukemia (AML) - Dynamic Market Forecast to 2026

出版日: | 発行: GlobalData | ページ情報: 英文 72 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.37円
急性骨髄性白血病 (AML) :動態市場の予測
出版日: 2017年12月22日
発行: GlobalData
ページ情報: 英文 72 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、急性骨髄性白血病 (AML) 治療薬市場について調査分析し、最新の予測 (規制、上市、治験イベントなど) について、体系的な情報を提供しています。

第1章 動態市場の予測概要

  • 関連調査
  • 将来の関連調査

第2章 エグゼクティブサマリー

第3章 学会:ASH 2017

第4章 イベント1

  • 主なアップデート
  • Jazz:Vyxeos (CPX-351)
  • 医師の見解
  • サマリー/動向
  • 情報源

第5章 イベント2

  • 主なアップデート
  • 競合情勢
  • Novartis:Rydapt (midostaurin)
  • 医師の見解
  • Arog:crenolanib
  • Astellas:gilteritinib
  • 医師の見解
  • サマリー/動向
  • 情報源

第6章 イベント3

  • 主なアップデート
  • Agios/Celgene:Idhifa
  • Agios:ivosidenib
  • 医師の見解
  • サマリー/動向
  • 情報源

第7章 イベント4

  • 主なアップデート
  • Pfizer:Mylotarg (gemtuzumab ozogamicin)
  • 医師の見解
  • 追加の治験アップデート
  • サマリー/動向
  • 情報源

第8章 追加イベント

  • 武田薬品工業:pevonedistat
  • 医師の見解

第9章 その他のイベント

  • さまざまなデベロッパー
  • 情報源

第10章 イベントカレンダー

第11章 付録

目次
Product Code: GDHC002FS

Acute Myeloid Leukemia (AML) is a disease that has been characterized by a stagnant pipeline and, consequently, the treatment paradigm has not substantially changed over time. Since the 1970s, the standard of care in newly diagnosed fit patients has been a chemotherapy bases 7 + 3 induction regimen (seven days of cytarabine + three days of an anthracycline), aimed at achieving a complete hematologic remission (CR), followed by consolidation therapy with cytarabine, or an allogeneic hematopoietic cell transplantation (HCT). In the last decade, a better understanding of the molecular basis of AML has encouraged the development of new targeted therapies, and this led to the launch of the first targeted agents in 2017. The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the AML space, including regulatory, commercial, and clinical events as well as understand how all of these events will impact the projected market forecast.

Scope

Key events covered in the Dynamic Market Forecast include -

  • Regulatory filings
  • Approval decisions
  • Pricing changes
  • Patent litigation
  • Clinical trial data announcements
  • Clinical trial failures
  • Clinical trial timeline updates

Components of the slide deck include -

  • Timeline of market-impacting events
  • Key clinical trial landscape updates
  • Conference coverage
  • Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective
  • Overview of updates to the forecast model based on anticipated future impact of events
  • Forward-looking events calendar listing expected key updates to the AML competitive space through December 2018

Reasons to buy

  • Recent Regulatory Events
  • Recent Commercial Events
  • Recent Clinical Events
  • New SOC expected for elderly t-AML and AML-MRC patients
  • Adoption of the First FLT3 Inhibitor, Rydapt, in the US and EU
  • Lack of Competition in the IDH+ AML Market Segment Benefits Celgene and Agios
  • US Approval of the First CD33 Targeting Agent, Mylotarg

Table of Contents

  • 1. Dynamic Market Forecast Overview 6
  • 1.1 Related Reports 7
  • 1.2 Upcoming Related Reports 8
  • 2. Executive Summary 9
  • 2.1 Key Updates to AML Market Dynamics 10
  • 2.2 Key Events in Update 11-12
  • 2.3 Updates to Treatment Algorithms 13-14
  • 2.4 Updates to Pipeline Competitive Assessment 15-16
  • 2.4 Market Insight on Key Events 17
  • 3. Conference Coverage - ASH 2017
  • 3.1 Selected Abstracts ASH2017 - AML 19-20
  • 4. Event 1: New SOC expected for elderly t-AML and AML-MRC patients
  • 4.1 Key Updates to the Frontline Setting - Elderly Patients 22
  • 4.2 Jazz, Vyxeos (CPX-351) 23-24
  • 4.3 What Do Physicians Think? 25
  • 4.4 Summary/Trends 26
  • 4.5 Sources 27
  • 5. Event 2: Adoption of the First FLT3 Inhibitor, Rydapt, in the US and EU
  • 5.1 Key Updates About the Use of FLT3 Inhibitors in the First- Line Setting 29
  • 5.2 Competitive Landscape of FLT3 Inhibitors in AML 30
  • 5.3 Novartis, Rydapt (midostaurin) 31
  • 5.4 What Do Physicians Think? 32
  • 5.5 Arog, crenolanib 33
  • 5.6 Astellas, gilteritinib 34
  • 5.7 What Do Physicians Think? 35
  • 5.8 Summary/Trends 36
  • 5.9 Sources 37
  • 6. Event 3: Lack of Competition in the IDH+ AML Market Segment Benefits Celgene and Agios
  • 6.1 Key Updates in IDH+ AML 39
  • 6.2 Agios/Celgene, Idhifa 40-41
  • 6.3 Agios, ivosidenib 42-44
  • 6.4 What Do Physicians Think? 45
  • 6.5 Summary/Trends 46
  • 6.6 Sources 47
  • 7. Event 4: US Approval of the First CD33 Targeting Agent, Mylotarg
  • 7.1 Key Updates on Mylotarg 49
  • 7.2 Pfizer, Mylotarg (gemtuzumab ozogamicin) 50
  • 7.3 What Do Physicians Think? 51
  • 7.4 Additional Clinical Trial Updates- CD33+ 52
  • 7.5 Summary/Trends 53
  • 7.6 Sources 54
  • 8. Additional Events
  • 8.1 Takeda, pevonedistat 56
  • 8.2 What Do Physicians Think? 57
  • 9. Other Events of Interest
  • 9.1 Various Developers 59
  • 9.2 Sources 60
  • 10. Events Calendar
  • 10.1 Key Events Expected to Occur in 2018 62
  • 11. Appendix
  • 11.1 Methodology 64
  • 11.2 Primary Research 65-66
  • 11.3 About the Authors 67-69
  • 11.4 About GlobalData 70
  • 11.5 Contact Us 71
  • 11.6 Disclaimer 72
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.